The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C.
about
Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis CLimiting the access to direct-acting antivirals against HCV: an ethical dilemma.Evaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients.The Current State of Liver Transplantation in the United States: Perspective From American Society of Transplant Surgeons (ASTS) Scientific Studies Committee and Endorsed by ASTS Council.Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong.Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.New hepatitis C therapies for special patient populations.
P2860
Q28080225-247C8F4E-681F-40CD-852D-768BB5534F95Q30244361-4161ADCB-B02F-4032-9385-23682EEA3235Q37064540-D5CF739A-AFCE-4268-8368-7C6E14F4E91BQ38804947-024D6403-82B6-4409-A6C3-D7D8C9B321A8Q40197476-374E5AEE-AAC7-468F-B4D8-47AEE8669E68Q40720905-239C3979-4178-45D3-A1F5-467D09A18A1EQ40899794-D66498F7-C3CA-4B28-9EFE-008AEC929E8F
P2860
The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The cost-effectiveness of nove ...... atment of chronic hepatitis C.
@en
type
label
The cost-effectiveness of nove ...... atment of chronic hepatitis C.
@en
prefLabel
The cost-effectiveness of nove ...... atment of chronic hepatitis C.
@en
P2860
P1476
The cost-effectiveness of nove ...... atment of chronic hepatitis C.
@en
P2093
Cherrishe Bickerstaff
P2860
P304
P356
10.1586/14737167.2015.1076337
P577
2015-08-10T00:00:00Z